
    
      This is a Phase 1,multi-center, randomized, double-blinded, placebo-controlled, outpatient
      study in healthy male and nonpregnant female subjects 18 to 40 years of age, inclusive. Three
      dosing cohorts to investigate the safety, reactogenicity, and immunogenicity of Recombinant S
      protein Severe Acute Respiratory Syndrome (SARS) vaccine, with and without aluminum hydroxide
      adjuvant manufactured by Protein Sciences Corporation, administered intramuscularly on Days 0
      and 28 at a dose of 5, 15, or 45 mcg; controls will receive the diluents/placebo without
      vaccine. Approximately 84 subjects are expected to be enrolled. All subjects will receive 2
      doses of their assigned treatment via IM injection approximately 28 days apart, followed by
      assessments at 6, 12, 15, 18, 21 and 24 months after the second dose.
    
  